<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02904850</url>
  </required_header>
  <id_info>
    <org_study_id>5615</org_study_id>
    <secondary_id>2013-A01122-43</secondary_id>
    <nct_id>NCT02904850</nct_id>
  </id_info>
  <brief_title>Validation of a Kinetic Model of Erlotinib</brief_title>
  <official_title>Validation of a Kinetic Model of Erlotinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several arguments are in favor of a therapeutic monitoring for the erlotinib, therefore, a
      pharmacokinetic (PK) has been prepared using data from the literature. This model must be
      validated at concentrations achieved in practice. This is a preliminary study before the
      implementation of a randomized trial confirming the therapeutic monitoring of erlotinib
      through this model.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Difference between plasma concentrations of erlotinib concentrations observed and predictive model</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of Blood levels outsized with severe side effects or compromising the vital prognosis (treatment response, adherence (assessed by the test Morisky Green)</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluation of interest to assay the active metabolite OSI-420 Observation between incidence of clinical problems (ineffectiveness, toxicity, adherence) and blood concentrations of erlotinib outsized.
Evaluation of the potential clinical benefit to provide a dosage of erlotinib</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>group of patients</arm_group_label>
    <description>Plasma dosage of erlotinib and OSI-420</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>group of patients</intervention_name>
    <description>Plasma dosage of erlotinib and OSI-420 is made from the blood usually taken Further information are collected in the medical record of the patient during the CT scan reassessment after collection.</description>
    <arm_group_label>group of patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients treated in the care departement of the hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients receiving treatment with erlotinib monotherapy for locally advanced or
             metastatic NSCLC either first line in patients with an activating mutation of the
             receptor EGF-R or patients with stable disease after 4 cycles of standard first-line
             chemotherapy with platinum or after failure of at least one prior chemotherapy regimen

          -  Age&gt; 18 years

          -  Subject has signed an informed consent

          -  Treatment initiated for at least 7 days or dosage changed for at least 7 days

        Exclusion Criteria:

          -  Contraindication to the use of drug

          -  Subject to exclusion period (as determined by a previous study or in progress)

          -  Inability to give informed information (subject in emergency situations, difficulties
             in understanding the subject, ...)

          -  Subject under judicial protection

          -  Subject under tutorship or curatorship

          -  Pregnancy (and woman of childbearing age without contraception)

          -  Breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Elisabeth QUOIX</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service Pneumologie Hôpitaux Universitaires Strasbourg 67 091 STRASBOURG cedex</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Elisabeth QUOIX</last_name>
    <phone>03 69 55 03 78</phone>
    <email>elisabeth.quoix@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service de Pneumologie Nouvel Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <state>Alsace</state>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bertrand MENNECIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain DUCOLONE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie PRIM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cesar MATAU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ashok PUROHIT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2014</study_first_submitted>
  <study_first_submitted_qc>September 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2016</study_first_posted>
  <last_update_submitted>September 13, 2016</last_update_submitted>
  <last_update_submitted_qc>September 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>locally advanced or metastatic</keyword>
  <keyword>erlotinib monotherapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

